Furthermore, treatment with neutralising anti-CSF-1R or anti-CSF1 antibodies can lead to a compensatory increase in granulocyte colony stimulating factor (CSF3), which stimulates an increase in neutrophils at the primary tumour site and in metastatic deposits. This evidence concerns the gene CSF1R and neoplasm.